{"schema_version":"secwatch.filing_event.v1","accession":"0001326110-26-000025","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.807486+00:00","generated_at":"2026-05-16T01:05:30.828610+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ImmunityBio reports 700% YoY revenue growth to $113M; first lung cancer approval in Saudi Arabia","bullets":["Full-year 2025 ANKTIVA net product revenue $113M (up ~700% YoY); Q4 net revenue $38.3M (up 431% YoY).","Unit sales volume increased 750% in 2025 vs 2024; cash and securities $242.8M as of Dec 31, 2025.","SFDA granted conditional accelerated approval for ANKTIVA + checkpoint inhibitors in metastatic NSCLC (Jan 2026) – first lung cancer approval globally.","Global regulatory footprint expanded to 33 countries across 4 jurisdictions (US, UK, EU, Saudi Arabia) in under two years.","Net loss attributable to common stockholders narrowed to $351.4M in 2025 from $413.6M in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001326110-26-000025","json":"https://secwatch.observer/filing/0001326110-26-000025.json","markdown":"https://secwatch.observer/filing/0001326110-26-000025.md","text":"https://secwatch.observer/filing/0001326110-26-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000025/0001326110-26-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000025/ibrx-20260223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:05:30.828610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}